Same-day dispatch: order by 3pm AEST
Order by 3 pm AEST
We are delighted to share an extract of an article about the challenges of alopecia treatments and the need for personalised treatments.
***
One of the biggest challenges with topical treatment of alopecia is the trial and error of finding the correct ingredients for best results. Given the time it takes for hair to enter anagen phase and new hair to grow in, it can take months for a given topical treatment to produce results. If the selected active pharmaceutical ingredient (API) or concentration isn’t suitable for the patient, this process would need to be started all over again with a new combination or strength, drawing out the process of finding suitable treatment. One technique to try to lessen the amount of trial and error in this process is looking at genetic markers to determine whether a treatment is likely to be efficacious. One of the most well-known examples is minoxidil. Minoxidil is a mainstay of topical and oral alopecia treatment, however, minoxidil itself is actually a prodrug. Minoxidil must be transformed by sulfotransferase enzyme A1 (SULT1A1) to the active minoxidil sulfate form in order to have an effect. It is thought that deficiency of SULT1A1 in the skin may be a major contributing factor to why only 40-50% of patients respond to topical minoxidil.1
Patients with this deficiency who desire to use a topical alopecia product must either use alternative therapy or consider a method to overcome this deficiency, either with elevated minoxidil concentrations or with the addition of another ingredient that upregulates SULT1A1. With regard to higher strength, though high-strength minoxidil may be associated with an increased risk of topical irritation, some studies have evaluated a high concentration specifically in patients who fail to respond to typical minoxidil concentrations such as 5%. For example, one study in women who had failed to respond to minoxidil 5% evaluated the efficacy of minoxidil 15% over 12 weeks and found clinically significant improvement in 60% of patients over the course of the study.2 However, other studies of high-concentration minoxidil, for example, another study that compared 5% minoxidil to 10% minoxidil or placebo in 90 men with androgenetic alopecia found that the higher concentration of minoxidil was not more effective than the standard 5% minoxidil concentration.3,4 Therefore, it is unclear if taking the approach of dosing every patient with high-concentration minoxidil is suitable for managing the risk of SULT1A1 deficiency.
The other approach, if topical minoxidil treatment is desired despite SULT1A1 deficiency, is the addition of an ingredient that upregulates existing SULT1A1. Retinoids are known to upregulate SULT1A1 gene transcription. Though there may be benefit associated with other retinoids as well, most of the limited data currently focuses on the impact of tretinoin on minoxidil responsiveness. Studies have evaluated tretinoin at concentrations between 0.01 to 0.1%. One small study that evaluated tretinoin 0.01% with minoxidil 5% vs minoxidil 5% alone did not note statistically significant benefit of the combination over individual therapy, though, studies on higher strengths (0.025%, 0.05%, and 0.1%) did note improved response. These studies are small, making comparative data on adverse events difficult to evaluate, though some studies did report numerical increased irritation or contact dermatitis in tretinoin/minoxidil combination groups.5,6
Knowing whether a patient is SULT1A1 deficient before initiating treatment could be key for determining whether minoxidil is likely to be beneficial and, if so, what the desired starting concentration should be or if combination treatment with a retinoid such as tretinoin should be considered at the outset.
References: